secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001601830-24-000217
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.01, 5.02, 7.01, 8.01, 9.01, 6.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion completes Exscientia acquisition; issues 102M shares, names new CFO
-----------------------------------------------------------------------------

- Acquisition of Exscientia effective Nov 20, 2024 via UK scheme; 0.7729 Recursion shares per Exscientia share; 102,138,419 shares issued.
- Exscientia ADSs (EXAI) delisted from Nasdaq; equity awards converted to Recursion options/RSUs using Exchange Ratio.
- CFO Michael Secora steps down; Ben Taylor (Exscientia's former CFO) appointed CFO of Recursion and President of Recursion UK.
- COO Tina Marriott transitions to Executive Advisor; CEO Chris Gibson adds President role; David Hallet named CSO; other exec promotions.
- Board expands to 8; Franziska Michor appointed Class II director. 2024 Inducement Equity Plan adopted, reserving 17.5M shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000217/0001601830-24-000217-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000217/rxrx-20241119.htm
  HTML page:      https://secwatch.observer/filing/0001601830-24-000217

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer